A comparison of the long‐term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

Objectives The durability of combination antiretroviral therapy (cART) regimens can be measured as time to discontinuation because of toxicity or treatment failure, development of clinical disease or serious long‐term adverse events. The aim of this analysis was to compare the durability of nevirapi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	HIV medicine 2011-05, Vol.12 (5), p.259-268
Hauptverfasser:	Reekie, J, Reiss, P, Ledergerber, B, Sedlacek, D, Parczewski, M, Gatell, J, Katlama, C, Fätkenheuer, G, Lundgren, JD, Mocroft, A
Format:	Artikel
Sprache:	eng
Schlagworte:	antiviral therapy Argentina - epidemiology Benzoxazines - adverse effects Benzoxazines - therapeutic use Drug Administration Schedule Drug Resistance Drug Therapy, Combination durability Europe - epidemiology Female HIV Infections - drug therapy HIV Infections - epidemiology HIV Infections - virology HIV Protease Inhibitors - therapeutic use HIV-1 Humans Israel - epidemiology long‐term adverse events Lopinavir Male Nevirapine - adverse effects Nevirapine - therapeutic use Prospective Studies Pyrimidinones - adverse effects Pyrimidinones - therapeutic use Reverse Transcriptase Inhibitors - therapeutic use Treatment Outcome Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objectives The durability of combination antiretroviral therapy (cART) regimens can be measured as time to discontinuation because of toxicity or treatment failure, development of clinical disease or serious long‐term adverse events. The aim of this analysis was to compare the durability of nevirapine, efavirenz and lopinavir regimens based on these measures. Methods Patients starting a nevirapine, efavirenz or lopinavir‐based cART regimen for the first time after 1 January 2000 were included in the analysis. Follow‐up started ≥3 months after initiation of treatment if viral load was
ISSN:	1464-2662 1468-1293
DOI:	10.1111/j.1468-1293.2010.00877.x